PR Newswire SHANGHAI, Oct. 22, 2024 SHANGHAI, Oct. 22, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced ...
PR Newswire TORONTO, Oct. 21, 2024 In this free webinar, learn how to effectively manage renal and hepatic impairment trials by leveraging site expertise, enhancing communication and using advanced clinical pharmacology tools. Attendees will ...
PR Newswire NEW HAVEN, Conn., Oct. 21, 2024 Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn., Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company ...
PR Newswire MONTREAL, Oct. 21, 2024 MONTREAL, Oct. 21, 2024 /PRNewswire/ - Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced ...
PR Newswire TAIPEI, Oct. 20, 2024 TAIPEI, Oct. 20, 2024 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced the successful completion of its Phase 1 single and multiple ascending dose (SAD/MAD) clinical study in ...
PR Newswire SPRINGFIELD, N.J., Oct. 18, 2024 SPRINGFIELD, N.J., Oct. 18, 2024 /PRNewswire/ -- Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company, focused on providing additional treatment options for cancer patients, ...
PR Newswire SHANGHAI, Oct. 18, 2024 SHANGHAI, Oct. 18, 2024 /PRNewswire/ -- LaNova Medicines Limited ("LaNova" or "The Company"), a privately-held clinical-stage innovation-driven biotech specializing in ADCs and immuno-oncology, announced ...
PR Newswire SAN FRANCISCO, Oct. 17, 2024 SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing ...
PR Newswire BUFFALO, N Y. and ATLANTA, Oct. 16, 2024 Updated results from a phase 3 clinical trial are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is treated. Details appear in a study published today in The New ...
PR Newswire SAN FRANCISCO and SUZHOU, China, Oct. 16, 2024 SAN FRANCISCO and SUZHOU, China, Oct. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, ...
Vanderbilt’s Phase I trial of VU319 demonstrates promising results for Alzheimer’s and schizophrenia
Late-breaking research finds no survival benefit from autologous stem cell transplant in mantle cell lymphoma patients with undetectable MRD.
Hypovolemic phlebotomy, removing 10% of blood before liver surgery, can cut transfusion needs by 50%, offering a safe, cost-effective way to reduce surgery risks.
Felzartamab, an investigational antibody, reduces triggers linked to IgA nephropathy, an autoimmune kidney disease, suggesting lasting clinical benefits.
Discover how FarrSight ®-Twin technology utilizes digital twins to revolutionize cancer clinical trials by simulating patient responses.
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers